查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1271182

杜氏肌营养不良症治疗市场：按治疗方法/治疗类型、最终用户、地区 - 规模、份额、前景、机会分析，2023-2030 年

Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, By End User, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 169 Pages | 商品交期: 2-3个工作天内

价格
简介目录

杜氏肌营养不良症 (DMD) 是一种肌营养不良症。 DMD 是一种遗传性疾病，其特征是进行性肌肉退化和无力，这是由于一种叫做抗肌萎缩蛋白的蛋白质发生变化，这种蛋白质可以防止肌肉细胞受损。 DMD 影响肌肉，导致肌肉无力随着时间的推移变得更糟。 杜氏肌营养不良症主要影响男性，但在极少数情况下也可能发生在女性身上。

市场动态：

杜兴氏肌营养不良症 (DMD) 患病率的增加、对新药和治疗的需求增加、研究和开发 (R&D) 的增加、公众对 DMD 和可用药物/治疗的认识的提高，是预计会促进 DMD 增长的主要因素全球杜氏肌营养不良症治疗市场。

例如，2022 年 5 月，Stealth BioTherapeutics Corp. 宣布美国食品和药物管理局 (FDA) 授予 Elamipretide 孤儿药资格，用于治疗杜氏肌营养不良症 (DMD)。

此外，2022 年 4 月，辉瑞公司将在美国开展第一项 3 期研究，评估针对杜氏肌营养不良症 (DMD) 门诊患者的研究性微型抗肌萎缩蛋白基因疗法 fordadistrogene movaparvovec。我们计划开设一个网站。

这项研究的主要特点

  • 本报告对杜氏肌营养不良症治疗市场进行了深入分析，提供了以 2022 年为基准年的预测期（2023 年至 2030 年）的市场规模和復合年增长率 (CAGR %)。
  • 它还阐明了各个细分市场的潜在创收机会，并概述了该市场具有吸引力的投资建议矩阵。
  • 它还提供有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
  • 根据以下参数（包括公司亮点、产品组合、主要亮点、财务业绩和战略）介绍全球杜氏肌营养不良症治疗市场的主要参与者。
  • 参与这项研究的主要公司包括辉瑞公司、BioMarin、Sarepta Therapeutics、Santhera Pharmaceuticals、PTC Therapeutics、Fibrogen Inc.、NS Pharma Inc.、Nobelpharma Co. Ltd.、Bristol-Myers Squibb 和 Eli Lilly和公司。
  • 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
  • 《全球杜氏肌营养不良症疗法市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以通过用于分析全球杜氏肌营养不良症治疗市场的各种战略矩阵来促进他们的决策。

这是目录：

第一章调查的目的和前提

  • 调查的目的
  • 先决条件
  • 缩写

第二章市场展望

  • 报告概述
    • 市场定义和范围
  • 执行摘要
    • 市场概况：按治疗方法和治疗类型分类
    • 市场概况：按最终用户分类
    • 市场概况：按地区
  • 连贯机会图 (COM)

第 3 章市场动态、法规和趋势分析

  • 市场动态
    • 杜氏肌营养不良症患病率上升
    • 缺乏标准化和严格的规章制度
    • 对新药和新疗法的需求增加
  • 影响分析
  • 主要亮点
  • 监管情景
  • 产品发布/批准
  • 害虫分析
  • 对 PORTER 的分析
  • 合併/收购场景

第 4 章杜氏肌营养不良疗法的全球市场——冠状病毒 (COVID-19) 大流行的影响

  • COVID-19 流行病学数据
  • 供应方和需求方分析
  • 经济影响

第 5 章全球杜氏肌营养不良症治疗市场：按治疗方法和治疗类型分类，2017-2030

  • 分子疗法
  • 类固醇疗法
  • 非甾体抗炎药 (NSAID)
  • 其他治疗方法和治疗类型

第 6 章全球杜氏肌营养不良症治疗市场：按最终用户分类，2017-2030

  • 医院/诊所
  • 门诊中心
  • 其他最终用户

第 7 章。2017-2030 年按地区分列的全球杜氏肌营养不良症治疗市场

  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第八章竞争格局

  • Pfizer Inc.
  • Fibrogen Inc.
  • BioMarin
  • Sarepta Therapeutics
  • Santhera Pharmaceuticals
  • PTC Therapeutics
  • NS Pharma Inc.
  • Nobelpharma Co. Ltd.
  • Bristol-Myers Squibb
  • Eli Lilly and Company

第 9 章

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI898

Duchenne muscular dystrophy (DMD) is a form of muscular dystrophy. It is a genetic disorder characterized by progressive muscle degeneration and weakness due to alterations of a protein called dystrophin, which helps keep muscle cells intact. DMD affects the muscles, leading to muscle wasting that gets worse over time. Duchenne muscular dystrophy occurs primarily in males, though in rare cases may affect females.

Market Dynamics:

Increase in prevalence of Duchenne muscular dystrophy (DMD), increase in demand for novel drugs or therapies, rise in research and development (R&D), and increase in awareness among people about DMD and available drugs/therapies are major factors expected to augment growth of the global Duchenne muscular dystrophy treatment market.

For instance, In May 2022, Stealth BioTherapeutics Corp. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to Elamipretide for the treatment of Duchenne Muscular Dystrophy (DMD).

Moreover, in April 2022, Pfizer Inc. planned to open the first U.S. sites in the Phase III study evaluating investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne Muscular Dystrophy (DMD).

Key features of the study:

  • This report provides in-depth analysis of the Duchenne muscular dystrophy treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global Duchenne muscular dystrophy treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer Inc., BioMarin, Sarepta Therapeutics, Santhera Pharmaceuticals, PTC Therapeutics, Fibrogen Inc., NS Pharma Inc., Nobelpharma Co. Ltd., Bristol-Myers Squibb, and Eli Lilly and Company.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global Duchenne muscular dystrophy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Duchenne muscular dystrophy treatment market.

Detailed Segmentation:

  • Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type
    • Molecular-based Therapies
    • Steroid Therapy
    • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • Other Therapeutic Approaches and Treatment Types
  • Global Duchenne Muscular Dystrophy Treatment Market, By End User
    • Hospitals/Clinics
    • Ambulatory Centers
    • Other End Users
  • Global Duchenne Muscular Dystrophy Treatment Market, By Geography
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles
    • Pfizer Inc.
    • Fibrogen Inc.
    • BioMarin
    • Sarepta Therapeutics
    • Santhera Pharmaceuticals
    • PTC Therapeutics
    • NS Pharma Inc.
    • Nobelpharma Co. Ltd.
    • Bristol-Myers Squibb
    • Eli Lilly and Company

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Therapeutic Approach and Treatment Type
    • Market Snapshot, By End User
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in prevalence of Duchenne muscular dystrophy
    • Lack of standardization and stringent rules/regulations
    • Increase in demand for novel drugs or therapies
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Duchenne Muscular Dystrophy Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Molecular-based Therapies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Steroid Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Other Therapeutic Approaches and Treatment Types
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

6. Global Duchenne Muscular Dystrophy Treatment Market, By End User, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospitals/Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Ambulatory Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
  • Other End Users
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)

7. Global Duchenne Muscular Dystrophy Treatment Market, By Geography, 2017-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
  • Middle East & Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2017-2030,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)

8. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fibrogen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BioMarin
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sarepta Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Santhera Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • PTC Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • NS Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Nobelpharma Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bristol-Myers Squibb
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us